Drug Combination Details
| General Information of the Combination (ID: C25680) | |||||
|---|---|---|---|---|---|
| Name | Periplocin NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Esophageal cancer
[ICD-11: 2B70]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | CTNNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | CTNNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Activity | FOXP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Eca-109 | CVCL_6898 | Esophageal squamous cell carcinoma | Homo sapiens | ||
| TE-1 | CVCL_1759 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| YES-2 | CVCL_E322 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| KYSE-30 | CVCL_1351 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| KYSE-410 | CVCL_1352 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| KYSE-510 | CVCL_1354 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination of the natural compound Periplocin and TRAIL induce esophageal squamous cell carcinoma apoptosis in vitro and in vivo: Implication in anticancer therapy. | |||||
